NCT07216651Completed
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
WeDosify Real-World Evidence: Evaluating a Clinical Decision Support and Patient Engagement Tool for Personalized Semaglutide Dosing in Adults With Overweight or Obesity in the United States
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 20 (actual)
- First submitted
- 10 Oct 2025
- Start date
- 23 Sept 2025
- Primary completion date
- 27 Feb 2026
- Lead sponsor
- Closed Loop Medicine
- Diseases
- Obesity
- NCT number
- NCT07216651
What you commit to
- Study type: Observational
- Participants enrolled: 20
- From 23 Sept 2025 to the primary completion date, 27 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with conditions that the Healthcare Professional (HCP) deems would prevent effective use of weighing scales and accurate self-monitoring or reporting of body weight.
- Failure to satisfy the responsible Healthcare Professional (HCP) of fitness to participate for any other reason.
Who the study is looking for
- Participants must be 18 years or older.
- Participants must have a diagnosis of either obesity or overweight.
- Participants must have initiated first-time semaglutide treatment within the past 4-12 weeks for the management of overweight or obesity, in line with United States Prescribing Information (USPI) and the clinical judgment of the responsible Healthcare Professional (HCP).
- Participants must have access to and be able to use suitable weighing scales to record their weight before or during consultations.
- Participants must provide written informed consent to participate in this study, including agreeing to adhere to the associated procedures.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amarillo Premier Research (an Objective Health Partnership) Coordinator of this site? Confirm its status | Amarillo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.